About Us

Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

A Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Social Media

Bluesky • Facebook • Instagram • LinkedIn • YouTube

Meet the Laser Focus World Team

Editorial

Sales

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology
My Watchlist
Indicators
Industrial Laser Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Kent Lake Issues Investor Presentation Detailing Opposition to Quanterix’s Proposed Merger with Akoya Biosciences

By: via Business Wire

Believes Transaction Significantly Undervalues Quanterix

Highlights that Quanterix’s Board is Essentially Rescuing Akoya at the Direct Expense of Quanterix Shareholders

Transaction Would Introduce Unnecessary Risk and Divert Cash and Management Focus Away from Quanterix’s Alzheimer’s Diagnostics Program, a Core Growth Opportunity

Calls on Quanterix Board to Answer Pressing Questions around Valuation, Process and Governance Issues in Connection with Transaction

Urges Shareholders to Vote Against Merger with Akoya to Protect the Future Value of Their Investment

Kent Lake PR LLC (“Kent Lake”) a holder of 7.25% of the outstanding common stock of Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), today issued a presentation to Quanterix shareholders in connection to Kent Lake’s opposition to the Company’s proposed transaction (the “Transaction”) with Akoya Biosciences (“Akoya”) (NASDAQ: AKYA).

Kent Lake’s full presentation is available at https://kentlake.s3.us-west-1.amazonaws.com/QTRX-AKYA_KLPRVoteNoDeck.pdf.

Highlights of the presentation include:

  • The Transaction is a bad deal for Quanterix shareholders – The Transaction inexplicably values Akoya nearly 5x higher than Quanterix, despite Quanterix’s superior mix, growth and market opportunity. It is essentially a bailout of Akoya. Quanterix’s shares have declined nearly 40% since the deal announcement.
  • Quanterix ended up bidding against itself for Akoya – As revealed in the S-4 related to the Transaction, other motivated, strategic potential buyers of Akoya walked away due to concerns around profitability, cash burn and leverage, leaving Quanterix as the only bidder. Reading the S-4 raises serious issues about the process that led to this Transaction.
  • The merger introduces unnecessary risk for Quanterix – Expected National Institute of Health funding cuts will further strain Akoya’s business, making Akoya’s balance sheet situation untenable and reinforcing Kent Lake’s belief that Akoya currently has little or no positive equity value.
  • Management is entrenched and conflicted – Certain directors remain on the Quanterix Board of Directors (the “Board”) despite failing to obtain majority voting from shareholders, while others appear to have undisclosed conflicts of interest that compromise their fiduciary duty to Quanterix shareholders, such as Dr. Ivana Magovčević-Liebisch’s director position at a Company with a material interest in Akoya.
  • The Transaction includes a provision where Quanterix would provide Akoya with $30 million in bridge financing absent any clear shareholder mandate – This is an egregious breach of the Board’s fiduciary duty to shareholders.
  • Quanterix has significant potential as a standalone company – The Transaction will divert focus away from Quanterix’s transformational Alzheimer’s testing opportunity, which, if pursued, could unlock substantial value.

In Kent Lake’s view, the incumbent Board can no longer be trusted to represent shareholders’ best interests. That is why Kent Lake recently nominated three highly qualified, independent candidates for election to Quanterix’s Board at the 2025 Annual Meeting of Shareholders. There are clear, superior alternatives for Quanterix on a standalone basis, and Kent Lake believes that abandoning the ill-fated Transaction would allow shareholders to realize greater value creation than combining with Akoya.

About Kent Lake

Kent Lake Partners LP is an investment fund founded by Ben Natter in 2019 with a focus on small and mid-capitalization public equities, particularly in the healthcare space. Mr. Natter has over a decade of successful public healthcare equity investing experience.

Certain Information Concerning the Participants

Kent Lake Partners LP (“Kent Lake Partners”), together with the other Participants (as defined below), intends to file a preliminary proxy statement and an accompanying GOLD universal proxy card with the Securities and Exchange Commission (“SEC”) to be used to solicit votes for, among other matters, the election of its slate of highly-qualified director nominees at the 2025 annual meeting of stockholders of Quanterix Corporation, a Delaware corporation (the “Company”).

KENT LAKE STRONGLY ADVISES ALL SHAREHOLDERS OF THE COMPANY TO READ THE PROXY STATEMENT AND OTHER PROXY MATERIALS, INCLUDING ITS GOLD PROXY CARD, AS THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. SUCH PROXY MATERIALS WILL BE AVAILABLE AT NO CHARGE ON THE SEC’S WEB SITE AT HTTP://WWW.SEC.GOV. IN ADDITION, THE PARTICIPANTS IN THIS PROXY SOLICITATION WILL PROVIDE COPIES OF THE PROXY STATEMENT WITHOUT CHARGE, WHEN AVAILABLE, UPON REQUEST. REQUESTS FOR COPIES SHOULD BE DIRECTED TO THE PARTICIPANTS’ PROXY SOLICITOR.

The participants in the proxy solicitation are currently anticipated to be Kent Lake Partners, Kent Lake PR LLC (“Kent Lake PR”) and Benjamin Natter (collectively, the “Kent Lake Parties”); and Alexander G. Dickinson, Bruce Felt and Hakan Sakul (the “Kent Lake Nominees” and collectively with the Kent Lake Parties, the “Participants”).

As of the date hereof, Kent Lake Partners directly beneficially owned 2,793,405 shares of the Company’s Common Stock, $0.001 par value per share (the “Common Stock”). Kent Lake PR, as the investment adviser and as the general partner to Kent Lake Partners, may be deemed to beneficially own the 2,793,405 shares of Common Stock beneficially owned by Kent Lake Partners. Mr. Natter, as the Managing Member of Kent Lake PR, may be deemed to beneficially own the 2,793,405 shares of Common Stock beneficially owned by Kent Lake Partners. None of the Kent Lake Nominees beneficially own any shares of Common Stock. All of the foregoing information is as of the date hereof unless otherwise disclosed.

Contacts

More News

View More
Pfizer is Locking in New Growth Through a New Acquisition
Via MarketBeat
Topics Artificial Intelligence
Tickers MTSR PFE
Copper Giant Freeport Slumps but Analysts See 33% Upside
Via MarketBeat
Tickers FCX SCCO
The BYD Opportunity: Tesla-Like Growth at a Fraction of the Price
Via MarketBeat
Topics Electric Vehicles
Tickers BYDDY LI TSLA
3 Reasons CoreWeave Could Be the Hottest AI Stock in Q4
Via MarketBeat
Topics Artificial Intelligence
Tickers CRWV NVDA
Accenture: Undervalued GenAI Leader or Snake Eating its Own Tail?
Via MarketBeat
Tickers ACN IBM
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.